Camlin Fine
Camlin Fine Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
3 of 5 strong
The short version
Vanillin Business**: Targeting 4,000 tons volume, with FY27 U.S. FY 2027 revenue guidance is maintained at INR 2,200 to 2,400 crores with EBITDA margin between 12%-14%.
From Camlin Fine's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- **Vanillin Business**: Targeting 4,000 tons volume, with FY27 U.S. vanillin sales estimated at 2,200 to 2,400 metric tons (both methyl and ethyl vanillin). Ethyl vanillin campaign planned for 600 tons with 50% order book coverage. Expect volume growth in Europe and U.S. as tariff impact eases.
- **Blends Business**: Expected to grow from INR1,050 crores in FY26 to over INR1,400 crores in FY27, supported by global sales force expansion.
- **Overall Revenue**: Projected top-line between INR2,200 to INR2,400 crores in FY27, with EBITDA margins of 12-14%.
- **Performance Chemicals**: Limited focus and small contribution expected; growth is not a priority.
- **Growth Challenges**: Working capital and logistics remain major constraints despite good order books.
- **Outlook**: Anticipate stable or improving market conditions with steady growth of 10-15% over next two quarters.
Profitability & Margins
See what Camlin Fine said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Camlin Fine Sciences is exploring converting an existing plant into a multipurpose facility to reduce raw material costs and improve efficiency.
- No specific mention of large-scale new capital expenditure; focus appears on strategic modifications and operational improvements.
- Investment in human capital continues, especially for scaling up the Blends business which is expected to grow exponentially.
- The company is strengthening its field force globally to support growth in Vinpai and Vitafor operations.
- Capital infusion is considered a last resort; current financing plans focus on debt options (structured and bank debt) to support growth and working capital needs.
- No explicit announcement of large future capex projects, but ongoing plant modifications and scaling of operations indicate targeted strategic investments.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Camlin Fine said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The ethyl vanillin campaign is planned for 600 tons.
- Currently, there is an order book covering 50% of this 600-ton campaign.
- Additional stock maintenance is planned since production shift from methyl to ethyl vanillin requires continuous market presence.
- Overall vanillin demand is projected around the 4,000-ton mark, considered very doable by management.
- The company faces challenges in longer working capital cycles, logistics, and cash flow rather than market demand.
- For FY 2027, the company is confident about fulfilling a certain quantum of supply regardless of pricing or cost fluctuations, supported by a healthy order book.
- In the Blends business, FY26 revenue was INR1,050 crores, with an expected increase to upwards of INR1,400 crores in FY27, backed by a growing global field force.
- U.S. vanillin volume target for FY27 is around 2,200 to 2,400 metric tons, with several contracts already secured.
Camlin Fine — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- NOCIL Ltd (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
- Indo Borax & Chemicals Ltd (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
- Rossari Biotech Ltd (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
- Pidilite Industries Ltd (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…
Frequently Asked Questions
What were Camlin Fine Q4 FY26 results?
Vanillin Business**: Targeting 4,000 tons volume, with FY27 U.S. FY 2027 revenue guidance is maintained at INR 2,200 to 2,400 crores with EBITDA margin between 12%-14%.
What is Camlin Fine share price analysis?
Camlin Fine currently shows a below-average growth signal. The stock trades at a P/E of N/A with a market cap of ₹1,993 Cr. Investors should review the full earnings analysis for detailed insights.
Is Camlin Fine planning capital expenditure?
Camlin Fine Sciences is exploring converting an existing plant into a multipurpose facility to reduce raw material costs and improve efficiency.
Keep Camlin Fine on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.